CG Oncology, Inc. (NASDAQ:CGON) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christina Rossi Other companies: Xilio Therapeutics, Inc. (Director · Since at least Oct 21, 2021); Blueprint Medicines Corp (Chief Operating Officer · Since at least Oct 29, 2018); Anika Therapeutics Inc. (Director · Until Apr 15, 2026 · Past) | Biopharmaceutical Executive & Board Member · Since at least Nov 24, 2025 |
| Leonard Post Other companies: uniQure N.V. (Director · Since at least Jun 17, 2020); Fulgent Genetics, Inc. (Director · Aug 1, 2022 – Aug 1, 2022 · Past); Praecis Pharmaceuticals Inc (Director · Feb 7, 2007 – Feb 7, 2007 · Past) | Chief Scientific Officer, Vivace Therapeutics · Since at least Jan 24, 2024 |
| Corleen Roche Other companies: Iovance Biotherapeutics, Inc. (Chief Financial Officer · Since at least Jul 15, 2025); Immunome, Inc. (Chief Financial Officer · Apr 19, 2021 – Jun 8, 2023 · Past) | CFO · Jan 24, 2024 – Apr 15, 2025 · Past |
| Isabel Kalofonos Other companies: Crinetics Pharmaceuticals, Inc. (Chief Commercial Officer · Since at least Dec 16, 2024); ImmunoGen Inc (SVP & CHIEF COMMERCIAL OFFICER · Apr 24, 2023 – Feb 12, 2024 · Past) | Chief Commercial Officer · Since at least Oct 13, 2026 |
| Jim DeTore Other companies: Kineta Inc. (See Remarks · Aug 4, 2016 – Aug 4, 2016 · Past); Bluebird bio Inc (Chief Financial Officer · Nov 10, 2014 – Dec 1, 2014 · Past) | Chief Financial Officer · Since at least Nov 17, 2025 |
| Josh Patterson Other companies: Gamida Cell Ltd (GENERAL COUNSEL · Jan 1, 2022 – Jan 31, 2024 · Past); Akcea Therapeutics Inc (General Counsel · Mar 6, 2020 – Oct 12, 2020 · Past) | See Remarks · Since at least May 13, 2024 |
| Susan E. Graf Other companies: Aardvark Therapeutics, Inc. (Board Member · Since at least Feb 12, 2025); Epizyme Inc (Chief Business Officer · Apr 25, 2016 – Feb 9, 2018 · Past) | Director · Since at least Jan 24, 2024 |
| Bob Lapetina Other companies: Immunome, Inc. (PAO and VP Finance & Corporate · Jan 2, 2024 – Jan 2, 2024 · Past) | See Remarks · Since at least Aug 5, 2025 |
| James Mulay Other companies: Fulgent Genetics, Inc. (Director · May 30, 2019 – May 30, 2019 · Past) | Director · Since at least Jan 24, 2024 |
| John McAdory Other companies: Oncolytics Biotech Inc. (Chief Operating Officer · Since Jan 14, 2026) | EVP of Strategy and Operations · Jan 14, 2026 – Nov 5, 2026 · Past |
| Victor Edward Tong Jr Other companies: Aardvark Therapeutics, Inc. (Director · Since at least Feb 12, 2025) | Director · Since at least Jan 24, 2024 |
| Victor Tong Other companies: Aardvark Therapeutics, Inc. (Managing Director · Since at least Nov 5, 2026) | Managing Director, Decheng Capital · Since at least Nov 5, 2026 |
| Ambaw Bellete | President and COO · Since at least Jan 24, 2024 |
| Arthur Kuan | Chairman, President & Chief Executive Officer · Since at least Jan 24, 2024 |
| Brian Liu | Managing Director, Longitude Capital · Since at least Jan 24, 2024 |
| Hong Fang Song | Director · Since at least Jan 24, 2024 |
| Jim Mulé | Director of Cell-based Therapies, Moffitt Cancer Center · Since at least Nov 5, 2026 |
| Megan Knight | Investor Relations · Since at least Sep 2, 2026 |
| Sarah Connors | Vice President, Communications and Patient Advocacy · Since at least Sep 2, 2026 |
| Swapnil Bhargava | Chief Technical Officer · Since at least Nov 5, 2026 |
| Vijay Kasturi | Chief Medical Officer · Since at least Jan 24, 2024 |